Agilent Technologies, Inc (A) – Is it a good time to invest in Agilent?

This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations

Agilent Technologies, Inc (A) (Q1FY23)

Highlights

The acquisition complements Agilent’s growing biopharma solutions, including new oligonucleotide analysis software for biopharma research, broader offerings for GPC/SEC
polymer analysis, the AssayMAP Bravo Protein Sample Prep Workbench 4.0, and investments in therapeutic oligonucleotide manufacturing.

Valuation

– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance of Agilent Technologies

Crispidea Coverage

No of Pages: 34

To download the previous quarter’s report click here

Follow our LinkedIn page for more updates